Denifanstat - Sagimet Biosciences
Alternative Names: ASC 40; TVB-2640Latest Information Update: 15 Oct 2024
At a glance
- Originator 3-V Biosciences
- Developer Ascletis; Mayo Clinic; Sagimet Biosciences; University of Kentucky; University of Texas Health Science Center at San Antonio
- Class Antiacnes; Antineoplastics; Benzonitrile; Cyclobutanes; Hepatoprotectants; Piperidines; Skin disorder therapies; Small molecules; Triazoles
- Mechanism of Action Fatty acid synthetase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Acne vulgaris; Glioblastoma
- Phase II Astrocytoma; Breast cancer; Non-alcoholic steatohepatitis; Non-small cell lung cancer
- Phase I Liver disorders; Prostate cancer
- Preclinical Liver cancer
- No development reported Colorectal cancer; Solid tumours
Most Recent Events
- 11 Oct 2024 Updated efficacy and adverse events data from the phase-IIb FASCINATE-2 trial in Non-alcoholic steatohepatitis released by Sagimet Biosciences , (NCT04906421),
- 01 Oct 2024 Denifanstat - Sagimet Biosciences receives Breakthrough Therapy status for Non-alcoholic steatohepatitis in USA
- 06 Jun 2024 Sagimet Biosciences plans for accelerated approval for Nonalcoholic Fatty Liver Disease